Scribe Therapeutics

Benjamin Oakes, Ph.D., CEO

Oct. 9 | 10:30am | FLW Ballroom F 

Alameda, CA

(Private)

Scribe Therapeutics is a genetic medicines company that is revolutionizing the development of in vivo genetic medicines to transform human health. The company employs the proprietary CRISPR by DesignTM approach to engineer bacterial immune systems into a premier suite of genome and epigenome editing tools built for unique advantages in activity, specificity, and deliverability that translate into safer and more effective therapies. Founded by renowned experts in genetic medicine, including CEO Benjamin Oakes and Nobel Laureate and CRISPR co-inventor Jennifer Doudna, Scribe is developing a leading portfolio of optimized in vivo genetic medicines to treat a spectrum of cardiometabolic diseases. $140M generated upfront from recently entered strategic partnerships with Sanofi and Lilly. Raised $100M Series B financing in 2021 led by Avoro, OrbiMed and Andreessen Horowitz, among other premier investors.

www.scribetx.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions